Revisiting the cardiovascular risk of hydroxychloroquine in RA.

Pers, Yves-Marie; Padern, Guillaume

Pers, Yves-Marie; Padern, Guillaume.

Pers YM; INSERM U1183, Institute for Regenerative Medicine and Biotherapy, CHU Montpellier and University of Montpellier, Montpellier, France. ym-pers@chu-montpellier.fr.
Padern G; INSERM U1183, Institute for Regenerative Medicine and Biotherapy, CHU Montpellier and University of Montpellier, Montpellier, France.

Nat Rev Rheumatol ; 16(12): 671-672, 2020 12.

Article in English | MEDLINE | ID: covidwho-811559

Subject(s)

Antimalarials/toxicity; Arthritis, Rheumatoid/drug therapy; Cardiovascular Diseases/chemically induced; Hydroxychloroquine/toxicity; Anti-Bacterial Agents/adverse effects; Anti-Bacterial Agents/therapeutic use; Anti-Infective Agents/adverse effects; Anti-Infective Agents/therapeutic use; Antimalarials/adverse effects; Antimalarials/therapeutic use; Azithromycin/adverse effects; Azithromycin/therapeutic use; COVID-19/epidemiology; COVID-19/virology; Cardiovascular Diseases/physiopathology; Drug Therapy, Combination; Heart Disease Risk Factors; Humans; Hydroxychloroquine/adverse effects; Hydroxychloroquine/therapeutic use; SARS-CoV-2/isolation & purification; Safety; Sulfasalazine/adverse effects; Sulfasalazine/therapeutic use; Time Factors; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Arthritis, Rheumatoid / Cardiovascular Diseases / Hydroxychloroquine / Antimalarials Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: Nat Rev Rheumatol Journal subject: Rheumatology Year: 2020 Document Type: Article Affiliation country: S41584-020-00521-x

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google